Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemia

Journal of Clinical Lipidology

Volumn 3, Issue 1, 2009, Pages 33-38

  Maki, Kevin C ^a   Lubin, Barry C ^b   Reeves, Matthew S ^a   Dicklin, Mary R ^a   Harris, William S ^c  

^a Provident Clinical Research   (United States)

^b formerly Hampton Roads Center for Clinical Research   (United States)

^c Nutrition and Metabolic Disease Research Center   (United States)

Author keywords

Dyslipidemia; Hypercholesterolemia; Omega 3 fatty acids; Statins; Triglycerides

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DYSLIPIDEMIA; ERUCTATION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; MONOTHERAPY; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

EID: 59249107912     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2008.12.007     Document Type: Article

References (32)

1. Liu J., Sempos C.T., Donahue R.P., et al. Non-high-density lipoprotein cholesterol and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol 98 (2006) 1363-1368
2. Kastelein J.J.P., van der Steeg W.A., Holme I., et al., for the TNT and IDEAL Study Groups. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117 (2008) 3002-3009
3. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354 (1999) 447-455
4. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 372 (2008) 1195-1196
5. Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369 (2007) 1090-1098
6. Pearson T.A., Laurora I., Chu H., et al. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160 (2000) 459-467
7. Davidson M.H., Maki K.C., Pearson T.A., et al. Results of the National Cholesterol Education Program (NCEP) Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 96 (2005) 556-563
8. Keevil J.G., Cullen M.W., Gangnon R., et al. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: Data from National Health and Nutrition Examination Survey 1999 to 2002. Circulation 115 (2007) 1363-1370
9. Davidson M.H., Stein E.A., Bays H.E., et al., for the COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemia patients: An 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 29 (2007) 1354-1367
10. Maki K.C., McKenney J.M., Reeves M.S., et al. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol 102 (2008) 429-433 Erratum, 2008;102:1425
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106 (2002) 3143-3421
12. Otvos J.D., Collins D., Freedman D.S., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorable changes by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113 (2006) 1556-1563
13. Block R.C., Harris W.S., Reid K.J., et al. EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls. Atherosclerosis 197 (2008) 821-828
14. Nordøy A., Bonaa K.H., Nilsen H., et al. Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. J Intern Med 243 (1998) 163-170
15. Durrington P., Bhatnagar D., Mackness M., et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin-treated patients with coronary heart disease and persisting hypertriglyceridemia. Heart 85 (2001) 544-548
16. Harris W.S., Miller M., Tighe A.P., et al. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 197 (2008) 12-24
17. Barter P., and Ginsberg H.N. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol 102 (2008) 1040-1045
18. Stein E.A., Lane M., and Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 81 Suppl. 4A (1998) 66B-69B
19. Stein E., Plotkin D., Bays H., et al. Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. Am J Cardiol 86 (2000) 406-411
20. Issacsohn I., Hunninghake D., Schrott H., et al. Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol 26 (2003) 18-24
21. Chan D.C., Watts G.F., Barrett P.H.R., et al. Regulatory effects of HMG CoA reductase inhibitors and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes 51 (2002) 2377-2386
22. Chan D.C., Watts G.F., Mori T.A., et al. Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. Am J Clin Nutr 77 (2003) 300-307
23. Dagnelie P.C., Rietveld T., Swart G.R., et al. Effect of dietary fish oil on blood levels of free fatty acids, ketone bodies, and triacylglyercol in humans. Lipids 29 (1994) 41-45
24. Harris W.S. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 65 suppl (1997) 1645S-1654S
25. Bucher H., Hengstler P., Schindler C., et al. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 112 (2002) 298-304
26. Pownall H., Brauchi D., Kilinc C., et al. Correlation of serum triglyceride and its reduction by w-3 fatty acids with lipid transfer activity and the neutral lipid composition of high-density and low-density lipoproteins. Atherosclerosis 143 (1999) 285-297
27. Roche H.M., and Gibney M.J. Long-chain n-3 polyunsaturated fatty acids and triacylglycerol metabolism in the postprandial state. Lipids 34 Suppl (1999) S259-S265
28. Cromwell W.C., and Otvos J.D. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 6 (2004) 381-387
29. McKenney J.M., and Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy 27 (2007) 715-728
30. Nambi V., and Ballantyne C.M. Combination therapy with statins and omega-3 fatty acids. Am J Cardiol 98 Suppl (2006) 34i-38i
31. McKenney J.M., Swearingen D., Di Spirito M., et al. Study of pharmacokinetic interaction between simvastatin and prescription omega-3 acid ethyl esters. J Clin Pharmacol 46 (2006) 785-791
32. Di Spirito M., Morelli G., Doyle R.T., Johnson J., and McKenney J. Effect of omega-3 acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adults. Expert Opin Pharmacother 9 (2008) 2939-2945